The patent name is "Novel Peptide to Inhibit Fat Accumulation and Pharmaceutical Composition to Prevent or Treat Obesity". Same & # 39;
This patent technology was developed in collaboration with Seoul National University, and deals with pharmaceutical compositions to prevent or treat obesity based on peptides to inhibit fat buildup. This peptide inhibits the differentiation of mesenchymal stem cells into adipocytes and inhibits the accumulation of adipose tissue, so that it can be used to prevent or treat obesity.
In women, estrogen levels decrease after menopause, accumulate abdominal fat and cause complications such as osteoporosis and diabetes.
A company official said, "Sibutramine, which is a common drug for appetite suppressants, is mostly used as an antidepressant, and most appetite suppressants are used as antidepressants." This drug causes various side effects, it also triggers non-alcoholic fatty liver disease. "
At present, preclinical studies of non-alcoholic interstitial diseases based on peptides are underway, and the US patent registration news will be resistant to research on diseases related to fat metabolism. "Until now, it was known that there was no treatment for non-alcoholic diseases.
Meanwhile, Naive is a biotech company that develops peptide-based fusion biomaterials for tissue regeneration, tissue regeneration, and drugs for the treatment of inflammatory diseases. Recently, as more and more aging people become more aggressive, this prepares clinical entries.[디지털뉴스국 김규리 기자][ⓒ 매일경제 & mk.co.kr, 무단전재 및 재배포 금지]